0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Critical appraisal and comparison of recommendations of clinical practice guidelines for the treatment of schizophrenia in children and adolescents: a methodological survey

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          The production of clinical practice guidelines (CPGs) has grown in the past years. Notwithstanding, the quality of these documents and their recommendations for the treatment of schizophrenia in children and adolescents is still unknown.

          Objective

          To assess the quality of the guidelines and recommendations for the treatment of schizophrenia in this population.

          Methods

          CPGs from 2004 to December 2020 were identified through a systematic search on EMBASE, MEDLINE, PsycINFO, PubMed, Epistemonikos, VHL, Global Index Medicus and specific CPG databases. The CPGs’ quality was independently assessed by three reviewers using AGREE II and they were considered of high quality if they scored ≥60% in domains 3 and 6. The evidence classification systems were described, the quality of recommendations was assessed in pairs using AGREE-REX and the recommendations were compared.

          Results

          The database search retrieved 3182 results; 2030 were screened and 29 were selected for full-text reading. Four guidelines were selected for extraction. Two CPGs were considered of high quality in the AGREE II assessment. We described the commonly agreed recommendations for each treatment phase. The pharmacological recommendations were described in all treatment phases. Scores of AGREE-REX were lower for psychosocial recommendations.

          Conclusion

          There are still few clinical studies and CPGs regarding schizophrenia in children and adolescents. The quality of the documents was overall low, and the quality of the recommendations report has much to improve. There is also a lack of transparency about the quality of the evidence and the strength of the recommendations.

          Protocol registration number

          CRD42020164899.

          Related collections

          Most cited references49

          • Record: found
          • Abstract: not found
          • Article: not found

          AGREE II: advancing guideline development, reporting and evaluation in health care.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology.

            The "Grades of Recommendation, Assessment, Development, and Evaluation" (GRADE) approach provides guidance for rating quality of evidence and grading strength of recommendations in health care. It has important implications for those summarizing evidence for systematic reviews, health technology assessment, and clinical practice guidelines. GRADE provides a systematic and transparent framework for clarifying questions, determining the outcomes of interest, summarizing the evidence that addresses a question, and moving from the evidence to a recommendation or decision. Wide dissemination and use of the GRADE approach, with endorsement from more than 50 organizations worldwide, many highly influential (http://www.gradeworkinggroup.org/), attests to the importance of this work. This article introduces a 20-part series providing guidance for the use of GRADE methodology that will appear in the Journal of Clinical Epidemiology. Copyright © 2011 Elsevier Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016

              Introduction The global burden of disease (GBD) studies have derived detailed and comparable epidemiological and burden of disease estimates for schizophrenia. We report GBD 2016 estimates of schizophrenia prevalence and burden of disease with disaggregation by age, sex, year, and for all countries. Method We conducted a systematic review to identify studies reporting the prevalence, incidence, remission, and/or excess mortality associated with schizophrenia. Reported estimates which met our inclusion criteria were entered into a Bayesian meta-regression tool used in GBD 2016 to derive prevalence for 20 age groups, 7 super-regions, 21 regions, and 195 countries and territories. Burden of disease estimates were derived for acute and residual states of schizophrenia by multiplying the age-, sex-, year-, and location-specific prevalence by 2 disability weights representative of the disability experienced during these states. Findings The systematic review found a total of 129 individual data sources. The global age-standardized point prevalence of schizophrenia in 2016 was estimated to be 0.28% (95% uncertainty interval [UI]: 0.24–0.31). No sex differences were observed in prevalence. Age-standardized point prevalence rates did not vary widely across countries or regions. Globally, prevalent cases rose from 13.1 (95% UI: 11.6–14.8) million in 1990 to 20.9 (95% UI: 18.5–23.4) million cases in 2016. Schizophrenia contributes 13.4 (95% UI: 9.9–16.7) million years of life lived with disability to burden of disease globally. Conclusion Although schizophrenia is a low prevalence disorder, the burden of disease is substantial. Our modeling suggests that significant population growth and aging has led to a large and increasing disease burden attributable to schizophrenia, particularly for middle income countries.
                Bookmark

                Author and article information

                Journal
                BMJ Open
                BMJ Open
                bmjopen
                bmjopen
                BMJ Open
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                2044-6055
                2023
                3 February 2023
                : 13
                : 2
                : e070332
                Affiliations
                [1 ]departmentGraduate Course in Pharmaceutical Sciences , University of Sorocaba , Sorocaba, Brazil
                [2 ]departmentGraduate Course in Pharmaceutical Sciences , Federal University of São Paulo , São Paulo, Brazil
                [3 ]departmentFamily Physician , Florianópolis Family Medicine Residency Program , Florianópolis, Brazil
                [4 ]departmentGraduate Course in Drugs and Medication , University of São Paulo , São Paulo, Brazil
                [5 ]departmentHealth Research Methodology , McMaster University , Mississauga, Ontario, Canada
                [6 ]departmentPan American Health Organization , World Health Organization , São Paulo, Brazil
                Author notes
                [Correspondence to ] Professor Luciane Cruz Lopes; luslopesbr@ 123456gmail.com
                Author information
                http://orcid.org/0000-0002-6608-1806
                http://orcid.org/0000-0001-8613-7953
                http://orcid.org/0000-0002-1178-2787
                http://orcid.org/0000-0002-4375-3729
                http://orcid.org/0000-0002-3684-3275
                Article
                bmjopen-2022-070332
                10.1136/bmjopen-2022-070332
                9906266
                36746538
                47a17e37-bc8f-4431-84dd-d182eb5cbf89
                © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

                This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:  http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 18 November 2022
                : 20 January 2023
                Categories
                Paediatrics
                1506
                1719
                Original research
                Custom metadata
                unlocked

                Medicine
                child & adolescent psychiatry,schizophrenia & psychotic disorders,mental health
                Medicine
                child & adolescent psychiatry, schizophrenia & psychotic disorders, mental health

                Comments

                Comment on this article